NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying - Cryomass Technologies (OTC:CRYM), N

The Dow Jones closed lower by more than 150 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

NetSol Technologies

The Trade: NetSol Technologies, Inc. (NASDAQ:NTWK) CEO Najeeb Ghauri acquired a total of 8,907 shares an average price of $1.94. To acquire these shares, it cost around $17,280.
What’s Happening: NETSOL Technologies reported a year-over-year decrease in fourth-quarter EPS results and issued FY24 revenue guidance.
What NetSol Technologies Does: NETSOL Technologies Inc is involved in providing information technology and enterprise software solutions.

Cryomass Technologies

The Trade: Cryomass Technologies Inc. (OTC:CRYM) CFO Philip Blair Mullin acquired a total of 62,000 shares at an average price of $0.15. To acquire these shares, it cost around $9,066.
What’s Happening: CryoMass Technologies signed a license agreement with a California cannabinoid ingredient producer, RubberRock Inc co-owned by famed extractor Brad Robertson, co-founder of Guild Extracts.
What Cryomass Technologies Does: Cryomass Technologies Inc designs, manufactures, and licenses field-mobile equipment for the handling of harvested cannabis, hemp, and other high-value plant material.

Check This Out: Top 4 Tech And Telecom Stocks That May Rocket Higher This Quarter

AIM ImmunoTech

The Trade: AIM ImmunoTech Inc. (NYSE:AIM) CEO and President Thomas K Equels acquired a total of 22,676 shares at an average price of $0.44. The insider spent $10,000 to buy those shares.
What’s Happening: AIM ImmunoTech announced that Roswell Park Comprehensive Cancer Center has reported the complete topline data from its Phase 1 study evaluating Ampligen (rintatolimod) as a component of a Chemokine-Modulating (CKM) regimen for the treatment of early-stage triple-negative breast cancer (TNBC).
What AIM ImmunoTech Does: AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases.

CRYMCryomass Technologies Inc

$0.000001-%

Overview

NTWKNETSOL Technologies Inc

$3.40-4.23%

AIMAIM ImmunoTech Inc

$0.5381-1.30%

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.